Sub-Saharan Africa is suffering from a disproportionate double burden of armed conflict and HIV infection. Nevertheless, the impact of the armed conflict on the HIV treatment outcomes in conflict ...

When it comes to a clinical study to evaluate the therapeutic effect of Shivagutika treatment in patients with HIV, it was ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

Achieving the 95-95-95 targets for HIV diagnosis, treatment, and viral load suppression to end the HIV epidemic hinges on eliminating structural inequalities, including intimate partner violence (IPV) ...

The absence of a lowering of HIV incidence in universal test and treat clusters most likely resulted from poor linkage to care. Policy change to HIV universal test and treat without innovation to ...

In Kenya, 1,378,457 people are living with HIV, with high prevalence reported among key population, including two out of ten ...

The Phase 1/2 study of VYD2311 was a randomized, double-blind, first-in-human clinical trial evaluating the safety and clinical pharmacokinetic (PK) profile of VYD2311 in 40 subjects across multiple ...

In a study of human immune cells infected with HIV, the virus that causes AIDS, scientists at Johns Hopkins Medicine say a molecule within HIV itself can be manipulated and amplified to force the ...

Assembly Biosciences reported positive Phase 1b results for ABI-4334 in chronic HBV, showing strong antiviral activity and favorable safety.

The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections.

Abstract Antiretroviral therapy (ART) initiated in the acute phase of HIV infection (AHI) results in a smaller viral reservoir. However, the impact of early HIV-specific T-cell responses on long-term ...